Denali Therapeutics (NASDAQ:DNLI) Stock Price Down 5.7% – Time to Sell?

Denali Therapeutics Inc. (NASDAQ:DNLI)’s stock price was down 5.7% during mid-day trading on Thursday . The stock traded as low as $21.12 and last traded at $21.1850. Approximately 474,514 shares changed hands during trading, a decline of 72% from the average daily volume of 1,719,490 shares. The stock had previously closed at $22.47.

Key Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: FDA accelerated approval of AVLAYAH — first FDA‑approved, brain‑penetrant enzyme replacement therapy for Hunter syndrome; includes a Rare Pediatric Disease Priority Review Voucher and supports Denali’s TransportVehicle™ platform. GlobeNewswire: FDA Approval
• Positive Sentiment: Goldman Sachs raised its price target to $40 and reiterated a Buy — represents sizable upside vs. current levels and signals institutional conviction. Benzinga: Goldman Sachs PT Raise
• Positive Sentiment: Stifel Nicolaus raised its target to $41 and moved to Buy — another high target lift adding upward analyst momentum. Benzinga: Stifel PT Raise
• Positive Sentiment: HC Wainwright bumped its target to $42 (Buy) and BTIG raised to $38 (Buy); Robert W. Baird raised to $32 (Outperform) — broad analyst upgrades today increase headline upside consensus. Benzinga: Analyst Raises TickerReport: BTIG Raise
• Neutral Sentiment: Denali is hosting a conference call/webcast today at 12:30 PM ET to discuss the FDA approval and launch plans — investors should listen for commercialization cadence, launch timing, pricing/reimbursement plans and supply capacity. Investor Webcast
• Neutral Sentiment: Short‑interest data reported in public feeds is effectively zero/ambiguous for late March — no clear short squeeze signal from the filings. (Reports appear to show 0 shares short, which is likely a reporting artifact.)
• Negative Sentiment: Accelerated approval is based on a biomarker (CSF heparan sulfate); continued approval may be contingent on confirmatory Phase 2/3 COMPASS results — this creates regulatory and commercialization execution risk. GlobeNewswire: Approval Details & COMPASS
• Negative Sentiment: Safety and tolerability issues — infusion‑related reactions, risk of hypersensitivity/anaphylaxis and other adverse events noted in prescribing information — could affect uptake and reimbursement. GlobeNewswire: Safety Info
• Negative Sentiment: Insider selling disclosed in recent summaries (executive sales cited) and mixed institutional moves are potential near‑term selling pressure factors. Quiver: Insider & Institutional Activity

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price target on shares of Denali Therapeutics in a report on Monday, March 2nd. The Goldman Sachs Group boosted their price objective on Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Wolfe Research began coverage on Denali Therapeutics in a research report on Monday, February 23rd. They issued a “peer perform” rating on the stock. UBS Group began coverage on Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Denali Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.64.

Denali Therapeutics Price Performance

The firm has a fifty day simple moving average of $20.41 and a 200 day simple moving average of $17.80. The company has a market capitalization of $3.20 billion, a PE ratio of -6.79 and a beta of 1.02. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.16 and a current ratio of 9.16.

Denali Therapeutics (NASDAQ:DNLI) last issued its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.02. During the same period in the previous year, the firm earned ($0.67) earnings per share. Equities analysts anticipate that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Insider Activity

In other Denali Therapeutics news, insider Alexander O. Schuth sold 17,218 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $284,097.00. Following the transaction, the insider directly owned 282,828 shares in the company, valued at $4,666,662. This represents a 5.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ryan J. Watts sold 35,198 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the transaction, the chief executive officer directly owned 296,833 shares in the company, valued at $4,897,744.50. This trade represents a 10.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 12.50% of the company’s stock.

Hedge Funds Weigh In On Denali Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Norges Bank bought a new position in Denali Therapeutics in the fourth quarter worth approximately $84,525,000. Holocene Advisors LP boosted its position in Denali Therapeutics by 677.8% during the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock valued at $45,531,000 after acquiring an additional 2,732,540 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Denali Therapeutics by 77.3% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,835,803 shares of the company’s stock valued at $63,329,000 after acquiring an additional 1,672,098 shares in the last quarter. Temasek Holdings Private Ltd increased its holdings in shares of Denali Therapeutics by 30.9% in the 4th quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after acquiring an additional 1,657,142 shares during the period. Finally, T. Rowe Price Investment Management Inc. increased its holdings in shares of Denali Therapeutics by 28.7% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after acquiring an additional 1,615,565 shares during the period. 92.92% of the stock is currently owned by institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.